From Bench to Bedside: Bringing Immunotherapy into the Clinic

Date and time: Tuesday, May 7, 2019 - 5:30 p.m.

Speaker: Miguel Sanjuan, BMS

Additional details: Event website

Learn from an industry veteran on how to channel innovative science into novel medicines.

Princeton Innovation Center BioLabs and global pharmaceutical company Bristol-Myers Squibb (BMS) invite you to attend an exclusive speaking event featuring Dr. Miguel Sanjuan.

About Dr. Miguel Sanjuan
Dr. Miguel Sanjuan is a group director in the BMS Immuno-Oncology Small Molecule Biology Department. At BMS, Dr. Sanjuan leads a team of world-class immunologists with a proven record of discovering cancer treatments. Prior to joining BMS in 2017, Dr. Sanjuan worked at Medimmune (AstraZeneca) for eight years, where he led a team of twenty innovative scientists focused on the discovery of novel molecules for the treatment of autoimmune disorders. Previously, he worked as a staff scientist at St. Jude Children’s Research Hospital, where he discovered a novel intracellular mechanism that linked for the first time the cellular self-digestion pathway, autophagy, with the elimination of extracellular pathogens. His cutting-edge research has collectively led to peer-reviewed publications, in journals such as Nature, Nature Immunology, Immunity, and the Proceedings of National Academy of Sciences, USA (PNAS).

Dr. Sanjuan received a bachelor’s degree in biology from the University of Seville and a doctorate in molecular biology from the Autonomous University of Madrid. He then trained as a postdoc fellow at Johnson & Johnson.

Networking: 5:30–6 p.m.
Presentation: 6 p.m.

The event is free.